KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Common Equity (2016 - 2026)

West Pharmaceutical Services has reported Common Equity over the past 18 years, most recently at $3.0 billion for Q1 2026.

  • Quarterly Common Equity rose 11.45% to $3.0 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.0 billion through Mar 2026, up 11.45% year-over-year, with the annual reading at $3.2 billion for FY2025, 18.41% up from the prior year.
  • Common Equity was $3.0 billion for Q1 2026 at West Pharmaceutical Services, down from $3.2 billion in the prior quarter.
  • Over five years, Common Equity peaked at $3.2 billion in Q4 2025 and troughed at $2.3 billion in Q1 2022.
  • The 5-year median for Common Equity is $2.7 billion (2023), against an average of $2.7 billion.
  • Biggest five-year swings in Common Equity: rose 27.18% in 2022 and later fell 6.9% in 2024.
  • Tracing WST's Common Equity over 5 years: stood at $2.7 billion in 2022, then rose by 7.3% to $2.9 billion in 2023, then decreased by 6.9% to $2.7 billion in 2024, then rose by 18.41% to $3.2 billion in 2025, then decreased by 5.84% to $3.0 billion in 2026.
  • According to Business Quant data, Common Equity over the past three periods came in at $3.0 billion, $3.2 billion, and $3.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.